Factors that influence the life expectancy of any cancer patient, including those who have been diagnosed with mesothelioma, vary. These include the type of cancer, the stage or extent to which it has spread at the time of diagnosis, and the overall health of the patient. Mesothelioma cancer is currently treated through three treatments, depending on the cancer location, the disease stage, and the patient’s general health and age. Learning simple yoga techniques can help improve general health by toning and strengthening muscles, improving flexibility, and improving general health and one’s state of mind.
There are three types of standard treatments used to treat malignant mesothelioma which include: surgery, radiation therapy, and chemotherapy. After chemotherapy comes surgery, where any tumor mass is removed. Pleurectomy/decortication removes the pleura so as to lessen pain or prevent the recurrence of pleural effusion. Certain substances may also be introduced into the space between the pleural membranes where fluid collects. It can and often is used in conjunction with chemotherapy as an extra defence against any small pockets of cancerous cells that might survive drug therapy. Most of these drugs circulate in the bloodstream in order to reach cancer cells in the body for the purpose of either killing these cancerous cells or for stopping them from dividing. These alternative therapies are used by patients coping with asbestos related disease as a form of pain management, to improve general health, and also to provide symptomatic relief.
Traditional mesothelioma treatments are the standard treatments for malignant mesothelioma, which is a cancerous disease affecting the mesothelial cells in tissues of the human body. Some cancer treatment centers are involved in clinical trials using biotherapy and immunotherapy. The median survival time is 17 months, with ten percent of patients living for three years after diagnosis. The American Cancer Society and National Cancer Institute are good resources for information on ongoing clinical trials and enrollment criteria.